Sort

Search

Search Bar
13/05/2022 Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease (vol 17, pg 1, 2022)
Visser, PJ, Reus, LM, Gobom, J, Jansen, I, Dicks, E, van der Lee, SJ, Tsolaki, M, Verhey, FRJ, Popp, J, Martinez-Lage, P, Vandenberghe, R, Lleo, A, Molinuevo, JL, Engelborghs, S, Freund-Levi, Y, Froelich, L, Sleegers, K, Dobricic, V, Lovestone, S, Streffer, J, Vos, SJB, Bos, I, Smit, AB, Blennow, K, Scheltens, P, Teunissen, CE, Bertram, L, Zetterberg, H, Tijms, BM. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease (vol 17, pg 1, 2022). Molecular Neurodegeneration. 2022; 17(1)DOI:10.1186/s13024-022-00540-0. PMID:35550177. IF:15.100(Q1/1D).
12/05/2022 Trends in the epidemiology of catheter-related bloodstream infections; towards a paradigm shift, Spain, 2007 to 2019
Badia-Cebada, L, Penafiel, J, Saliba, P, Andres, M, Camara, J, Domenech, D, Jimenez-Martinez, E, Marron, A, Moreno, E, Pomar, V, Vaque, M, Limon, E, Masats, U, Pujol, M, Gasch, O. Trends in the epidemiology of catheter-related bloodstream infections; towards a paradigm shift, Spain, 2007 to 2019. Eurosurveillance. 2022; 27(19)DOI:10.2807/1560-7917.ES.2022.27.19.2100610. PMID:35551704. IF:19.000(Q1/1D).
12/05/2022 Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Burger, JA, Robak, T, Demirkan, F, Bairey, O, Moreno, C, Simpson, D, Munir, T, Stevens, DA, Dai, S, Cheung, LWK, Kwei, K, Lal, I, Hsu, EM, Kipps, TJ, Tedeschi, A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6)DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2.600(Q3/7D).
10/05/2022 Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas The RACECAT Randomized Clinical Trial
de la Ossa, NP, Abilleira, S, Jovin, TG, Garcia-Tornel, A, Jimenez, X, Urra, X, Cardona, P, Cocho, D, Purroy, F, Serena, J, Manzanera, LS, Vivanco-Hidalgo, RM, Salvat-Plana, M, Chamorro, A, Gallofre, M, Molina, CA, Cobo, E, Davalos, A, Ribo, M, Martí-Fàbregas J., RACECAT Trial Investigators. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas The RACECAT Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2022; 327(18)DOI:10.1001/jama.2022.4404. PMID:35510397. IF:120.700(Q1/1D).